Optimized sgRNA to enhance targeting accuracy and editing efficiency.
The single-guide RNA (sgRNA) market is expanding rapidly, fueled by the widespread adoption of gene editing and the accelerating transition from research to clinical therapeutics. This shift is driving surging demand for high-quality GMP-grade sgRNA.
Advances in sgRNA manufacturing technology and surging investment in gene-editing research are making scalable, high-fidelity sgRNA production critical to delivering next-generation transformative therapies.
For successful gene therapy development, sgRNA must meet stringent quality requirements:
Our platform process and GMP manufacturing ensure these standards through stringent controls and robust quality system.
CoJourney offers a state-of-the-art sgRNA GMP manufacturing platform engineered for consistency, yield, and scale. Our rigorous process controls and validated assays ensure your project meets the highest quality standards, delivering:
CoJourney delivers a state-of-the-art sgRNA GMP manufacturing platform backed by rigorous process controls and analytical validation. We focus on consistency, high yield, and scalable production for sequences under ~130 bases.
Optimized timelines for GMP production
Efficient batch-scale manufacturing
Advanced purification & validated analytical methods
Documentation & compliance support across global markets
Partner with CoJourney to de-risk and accelerate your sgRNA-based therapeutic programs.
Download our brochure to learn how CoJourney can help to de-risk and accelerate your sgRNA-based therapeutic programs.
